港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

481.995

-14.725-2.96%

漲家數：8

跌家數：21

平家數：4

市盈率：- -

高：497.296

開：496.590

低：481.390

收：496.720

成交量：7,152.05萬

成交額：19.73億

市值：3,064.14億

流通市值：2,723.68億

資料載入中...

總覽新聞資訊

歸創通橋(02190)9月15日耗資約112.75萬港元回購5.5萬股

交銀國際：維持德琪醫藥(06996.HK)「買入」評級目標價10港元

可以多活8.2個月！國產雙抗挑戰全球腫瘤「藥王」總生存期勝出

港股異動 | 心瑋醫療-B(06609)升逾5% 上半年缺血性卒中業務收入持續穩增公司穩步推進A股IPO進程

港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准

禮邦醫藥－Ｂ(09637)股價顯著上升14.696%，現價港幣$26.38

阿斯达克财经

渠道紅利見頂，主動投研掉隊工銀瑞信的權益短板誰來補？

同源康醫藥－Ｂ(02410)股價大幅上升15.635%，現價港幣$3.55

阿斯达克财经

浙商證券：醫療器械子版塊多因素交織低值耗材板塊表現亮眼

港股異動 | 同源康醫藥-B(02410)漲逾10% 大股東增持提振市場信心此前核心品種已順利獲批

市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點

勁方醫藥-B(02595.HK)：GFH375(口服KRAS G12D抑制劑)II期單藥治療經治NSCLC優效數據登陸2026世界肺癌大會口頭報告

勁方醫藥-B(02595)：GFH375(口服KRAS G12D抑制劑)II期單藥治療經治NSCLC優效數據登陸2026世界肺癌大會口頭報告

亞盛醫藥與北京大學達成戰略合作，共築血液腫瘤協同創新體系

智通港股早知道 | 國產創新藥WCLC數據密集兑現投行看好中國CRO/CDMO復甦明確

對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內

每日经济新闻

創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據

每日经济新闻

億騰嘉和(06998.HK)9月14日斥資約170.16萬港元回購100萬股

CRO板塊強勢走高！多家CRO上市公司解密業務近況

微博财经-财道工作室

智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":481.99478,"timestamp":1789544587703,"preClose":496.71994,"halted":0,"volume":71520524,"delay":0,"changeRate":-0.029645,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-14.725159,"latestTime":"09-16 15:43:07","open":496.59045,"high":497.2955,"low":481.3899,"amount":1973161022,"amplitude":0.032021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789546200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":3.69899,"peRate":164.598608,"turnoverRate":0.002721,"increases":8,"decrements":21,"flats":3,"marketCap":306413936656,"floatMarketCap":272368245128},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":497.2955,"amplitude":0.032021,"preClose":496.71994,"low":481.3899,"pbRate":"3.69899","latestPrice":481.99478,"volume":71520524,"delay":0,"open":496.59045,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.388,"twentyDayClose":492.831,"sixtyDayClose":437.952,"secType":"PLATE","market":"HK","turnoverRate":0.002721,"peRate":164.598608,"marketCap":306413936656,"floatMarketCap":272368245128,"timestamp":1789544587703,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":21,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667643414","title":"歸創通橋(02190)9月15日耗資約112.75萬港元回購5.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643414","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:36","pubTimestamp":1789465011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2026年9月15日耗资约112.75万港元回购5.5万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","BK1100","BK1587","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667170648","title":"交銀國際：維持德琪醫藥(06996.HK)「買入」評級 目標價10港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667170648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667170648?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:55","pubTimestamp":1789462559,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648612","title":"可以多活8.2個月！國產雙抗挑戰全球腫瘤「藥王」總生存期勝出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648612","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667648612?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:46","pubTimestamp":1789461960,"startTime":"0","endTime":"0","summary":"2026年世界肺癌大会，对于国产创新药而言，不只是“被看见”，更要回答一个硬核的问题：到底能不能让患者活得更久。继翰森制药ADC药物刷新全球小细胞肺癌二线治疗最长总生存期（OS）纪录外，另外一款国产创新药挑战全球肿瘤“药王”总生存期的数据也揭晓了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874734252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874734252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2461242641.AUD","LU1934455863.HKD","LU1989772923.USD","KURE","LU2023250843.SGD","IE00B4R5TH58.HKD","LU2476274720.SGD","LU0823416689.USD","LU1961090484.USD","SG9999002232.USD","09926","LU0477156953.USD","LU0348783233.USD","SG9999001176.SGD","LU0965508806.USD","LU0348825331.USD","LU2361044865.SGD","LU2399975544.HKD","LU2360032135.SGD","SG9999002224.SGD","BK4533","IE00BBT3K403.USD","LU0289739343.SGD","LU1989771016.USD","LU0208291251.USD","LU1941712348.USD","FHLC","LU0070302665.USD","LU0634319403.HKD","SG9999001440.SGD","LU1032466523.USD","MRK","GDOC","XLV","LU0348735423.USD","VHT","IE00BFTCPJ56.SGD","LU2488822045.USD","LU2778985437.USD","LU1116320901.HKD","IE00BLSP4452.SGD","BK4559","LU0098860793.USD","LU0122379950.USD","LU1023059063.AUD","PPH","LU1116320737.USD","LU0472753341.HKD","LU1066051225.USD","IE00B543WZ88.USD","LU0980610538.SGD","LU0130517989.USD","IE00BLSP4239.USD","LU1093756168.USD","LU1035773651.USD","LU2125154778.USD","LU2125909247.SGD","LU0417516902.SGD","LU0511384066.AUD","LU1162221912.USD","IE00B2B36J28.USD","LU1934455277.USD","LU0861579265.USD","RXL","BK4550","LU0203347892.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU0124676726.USD","LU1571399168.USD","BMED","BK4585","LU1061106388.HKD","LU1989772840.SGD","IE00BSNM7G36.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU0130102774.USD","LU0238689110.USD","LU1093756325.SGD","LU0868494617.USD","LU0868494708.USD","LU2125154935.USD","LU0289961442.SGD","LU0942090050.USD","SG9999001176.USD","LU0265550359.USD","PAWZ","IHE","IE0002141913.USD","LU0006306889.USD","LU0689626769.HKD","LU1923622614.USD","BK4516","LU0069063385.USD","LU0648001328.SGD","LU2361045086.USD","LU1585245621.USD","LU0965509010.AUD","LU1066051498.USD","LU0965509101.SGD","HRTS","LU0320765489.SGD","LU1941712264.USD","LU0348784397.USD","LU2023250504.SGD","LU0266013472.USD","LU1929549753.HKD","SG9999014559.SGD","LU2491050154.USD","LU0348767384.USD","BK4007","LU0106261372.USD","LU0417516738.SGD","LU0234572021.USD","LU0561508036.HKD","LU2491050071.SGD","SG9999014567.USD","LU1037948897.HKD","IXJ","LU0057025933.USD","LU1794554557.SGD","LU1983299246.USD","LU2361044949.HKD","LU0348766576.USD","IE000M9KFDE8.USD","LU2089984988.USD","LU1974910355.USD","LU0348827113.USD","LU2125909593.SGD","TRUH","JDOC","LU1066051811.HKD","LU2357627491.SGD","LU0320765646.SGD","SG9999015358.SGD","LU2491049909.HKD","LU1430594728.SGD","LU1201861249.SGD","IE00B1BXHZ80.USD","LU0211331839.USD","LU1291159041.SGD","LU2433249047.HKD","LU1917777945.USD","FTXH","LU0965509283.SGD","LU2468319806.SGD","LU2112291526.USD","LU0265550946.USD","IE00BJT1NW94.SGD","LU2324357040.USD","BK1574","LU1037948541.HKD","LU2106854487.HKD","BK1161","IE0009355771.USD","LU0985320562.USD","LU1057294990.SGD","LU0058720904.USD","LU1934455194.USD","SGXZ57979304.SGD","IYH","LU0289739699.SGD","LU0417516571.SGD","LU0203345920.USD","BK4534","LU2476274308.USD","LU0859254822.USD","LU1699723380.USD","BK4588","SG9999014575.USD","SG9999013999.USD","IE00B5MMRT66.SGD","SG9999015341.SGD","SG9999014542.SGD","LU1069347547.HKD","LU0540923850.HKD","IE00BN8TJ469.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667526611","title":"港股異動 | 心瑋醫療-B(06609)升逾5% 上半年缺血性卒中業務收入持續穩增 公司穩步推進A股IPO進程","url":"https://stock-news.laohu8.com/highlight/detail?id=2667526611","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667526611?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 14:15","pubTimestamp":1789452903,"startTime":"0","endTime":"0","summary":"2026年上半年，公司缺血性卒中业务收入继续保持稳定增长。值得关注的是，心玮医疗计划于2026年下半年向上海证券交易所提交首次公开发行A股并在科创板上市的申请，预计拟募集资金规模约5亿元，预计发行比例约15%，并将继续根据公司经营情况及监管要求推进股票回购、现金分红等工作。中信建投表示，公司正稳步推进A股IPO进程，未来有望通过A股IPO上市进一步提升资本市场流动性，加速公司在全球市场的商业化布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06609","03130","02827","FRHC","BK4127","82846","BK1100","BK1587","02846","KCAI","BK4585","83188","BK1574","159982","83130","03188","REDS","BK1147","VXUS","KCE","07233","399300","BK4588","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619385","title":"港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667619385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:36","pubTimestamp":1789450580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B午后飙升逾17%。消息面上，礼邦医药近日宣布，AP308用于治疗IgA肾病的新药临床试验申请近日获美国食品药品监督管理局批准。公司计划于近期启动AP308的首次人体临床试验。AP308的IND获批标志着这一首创新药由临床前研究迈入临床开发阶段。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09637","BK1574","09939","159938","VXUS","BK1191","BK1515","BK4585","KCAI","LABU","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616045","title":"禮邦醫藥－Ｂ(09637)股價顯著上升14.696%，現價港幣$26.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616045","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616045?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:30","pubTimestamp":1789450200,"startTime":"0","endTime":"0","summary":"[上升股]礼邦医药－Ｂ(09637) 股价在下午01:30比前收市价显著上升14.696%，现股价为港币$26.38。至目前为止，今日最高价为$26.38，而最低价为$22.78。总成交量为84.79万股，总成交金额为港币$2.12千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151589/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151589/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","09637","BK1515","BK1161","BK1574","BK1191","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616501","title":"渠道紅利見頂，主動投研掉隊  工銀瑞信的權益短板誰來補？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616501","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616501?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 11:54","pubTimestamp":1789444440,"startTime":"0","endTime":"0","summary":"依托大股东工商银行遍布全国的庞大渠道网络，工银瑞信是国内银行系公募的代表性机构，总管理规模迈上 2.56 万亿元台阶，养老金业务也位居行业前列。当渠道红利逐渐见顶，产品业绩、人才体系、内控治理三重压力接踵而至，这家头部公募正迎来一场绕不开的考验。明星产品深度回撤风格漂移引争议根据工商银行年报披露的工银瑞信经营数据，2025 年全年，公司实现净利润 30.07 亿元，同比增长 42.5%；进入 2026 年上半年，公司增长势头进一步提速。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-15/doc-inirwsee3872484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667184356","title":"同源康醫藥－Ｂ(02410)股價大幅上升15.635%，現價港幣$3.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2667184356","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667184356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:44","pubTimestamp":1789440240,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在上午10:43比前收市价大幅上升15.635%，现股价为港币$3.55。至目前为止，今日最高价为$3.55，而最低价为$3.175。总成交量为231.15万股，总成交金额为港币$775.694万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151343/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151343/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","02410","BK1574","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690153","title":"浙商證券：醫療器械子版塊多因素交織 低值耗材板塊表現亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690153","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690153?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:06","pubTimestamp":1789437973,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，浙商证券发布研报称，展望2026年下半年，该行认为医疗器械子版块外部发展环境和内部发展逻辑略有不同，多因素交织。其他子版块净利润受外汇损益等因素较大营运能力：家用医疗板块、IVD、低值耗材板块应收账款周转率均有提升，考虑到存货周转率和资产周转率维持稳定，IVD和低值耗材板块ROE有所提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","MDEV","AGNG","IEIH","PTH","RSPH","09996","BK1100","601878","GDOC","HART","LNGR","BK0276","BK1583","BK1574","159883","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690691","title":"港股異動 | 同源康醫藥-B(02410)漲逾10% 大股東增持提振市場信心 此前核心品種已順利獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690691","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690691?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:02","pubTimestamp":1789437751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早震荡走高，截至发稿，涨10.1%，报3.38港元，成交额389.48万港元。此外，今年8月底，同源康医药披露其核心品种顺利获批，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得NMPA批准，在国内附条件上市，适应症为具有EGFR 19DEL或L858R置换突变，并伴有CNS转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK4585","BK4588","KCAI","BK1574","VXUS","09939","02410","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667697929","title":"市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697929","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667697929?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 09:28","pubTimestamp":1789435718,"startTime":"0","endTime":"0","summary":"　　昨日市场延续弱势震荡，三大指数全线收跌，量能进一步萎缩，仅剩1.63万亿，通常而言持续缩量震荡后市场面临着变盘节点，静待后续的方向选择。　　网络安全概念成为昨日市场最大亮点，逆势走出独立走强行情。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/zldongxiang/20260915/32369725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LOUP","BK1161","SPAM","159992","IBBQ","SKYY","BK4588","DRES","HAKY","FWD","GSFP","ANEW","BPAY","WCBR","NSI","BK1574","MVPS","TEKX","BUG","KOMP","CRWC","XT","BCTK","CRTC","BK4585","FDIF","NBDS","PSWD","CRWL","MEDX","UCYB","IHAK","06978","LNGR","TEK","TEKY","CIBR","FITE","PSCT","INVN","USMD","FDFF","EIS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667694130","title":"勁方醫藥-B(02595.HK)：GFH375(口服KRAS G12D抑制劑)II期單藥治療 經治NSCLC優效數據登陸2026世界肺癌大會口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2667694130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667694130?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 08:24","pubTimestamp":1789431858,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02595","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134694","title":"勁方醫藥-B(02595)：GFH375(口服KRAS G12D抑制劑)II期單藥治療 經治NSCLC優效數據登陸2026世界肺癌大會口頭報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134694","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134694?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 08:24","pubTimestamp":1789431858,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 发布公告，GFH375单药治疗经治KRASG12D突变型非小细胞肺癌的II期试验更新数据，于当地时间9月14日登陆今年在首尔举行的世界肺癌大会口头报告。截至2026年9月4日，共有75名KRASG12D突变型NSCLC患者接受600mgQD口服GFH375治疗，其中98.7%的患者存在远处转移，包括骨转移、脑转移(16%)、肝转移等。截至2026年6月17日，75名患者接受GFH375单药治疗后显示安全性/耐受性可控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02595","09939","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690236","title":"亞盛醫藥與北京大學達成戰略合作，共築血液腫瘤協同創新體系","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690236","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690236?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:40","pubTimestamp":1789429200,"startTime":"0","endTime":"0","summary":"双方将整合临床资源与创新研发优势，共筑血液肿瘤协同创新体系，加快该领域创新成果的临床转化，为患者带来更多获益。北京大学人民医院作为北大医学体系的重要组成部分和国家医学中心建设单位，在血液肿瘤等重大疾病诊疗与研究领域积淀深厚。亚盛医药一直以来与北京大学有着深厚的合作根基与相互的信任。\" 此次战略合作标志着亚盛医药与北京大学在血液肿瘤领域的协同创新进入新阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5046875_ZH46875_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1574","BK1161","AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691412","title":"智通港股早知道 | 國產創新藥WCLC數據密集兑現 投行看好中國CRO/CDMO復甦明確","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691412?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:29","pubTimestamp":1789428595,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。经初步测算，本次交易完成后，一汽股份将成为公司第二大和具有战略影响力的股东;本次交易预计构成重大资产重组及关联交易，不构成公司实际控制人变更，不构成重组上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","IE00B5MMRT66.SGD","BK1144","BK1183","LU1226287875.USD","LU1951186391.HKD","IE00BZ08YT58.USD","LNGR","BK1191","06978","LU0326950275.SGD","BK1119","06871","HK0000165453.HKD","IBBQ","MEDX","VXUS","LU0315179316.USD","LU0501845795.SGD","LU1152091754.HKD","BK1539","BK4139","LU1226288170.HKD","LU1813983027.USD","KURE","02889","IE0008368742.USD","CDMO","IE00B543WZ88.USD","LU1960683339.HKD","159992","LU1993786604.SGD","BK1574","SG9999004220.SGD","01911","LU1328277881.USD","BK4585","KCAI","LU0314109678.HKD","LU1008478684.HKD","LU0140636845.USD","LU1226287792.SGD","01093","BK4588","IE0008369823.USD","LU2039709279.SGD","BK1521","02238","BK1161","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667660668","title":"對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","MEDX","IE00B5TLWC47.USD","LU2272731865.HKD","06978","LU1992135472.HKD","IBBQ","BK1161","BK4588","LU2272731782.SGD","PPH","LU2322448957.HKD","159992","LU2272731600.USD","LU2473716301.USD","LU2322448791.USD","LU1992135399.USD","XPH","IBB","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667366424","title":"創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2667366424","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667366424?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 22:40","pubTimestamp":1789396854,"startTime":"0","endTime":"0","summary":"9月14日，低迷了近一个月的创新药板块迎来上涨。截至收盘，创新药（BK1106）、创新药（HK1105）分别上涨2.38%、3.42%。个股方面，诺诚健华、映恩生物、乐普生物、康方生物领跑港股。消息面上，9月12日—15日召开的“2026世界肺癌大会（WCLC）”成为板块最强催化，多家国产药企密集交出重磅临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873752330.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873752330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","LNGR","06978","MEDX","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667664958","title":"億騰嘉和(06998.HK)9月14日斥資約170.16萬港元回購100萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667664958","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667664958?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 22:28","pubTimestamp":1789396096,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1583","06998","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466104","title":"CRO板塊強勢走高！多家CRO上市公司解密業務近況","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466104","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 21:08","pubTimestamp":1789391280,"startTime":"0","endTime":"0","summary":"在互动平台与机构调研中，多家具备CRO业务的上市公司近期密集回应市场关切，披露了订单、产能及全球化布局的最新进展。2026 年上半年，公司实现 CRO 销售收入 4,513.95 万元， 较上年同期增长 10.91%。截至 2026 年上半年末，客户群体不断扩大，累计服务超过 16,900 家研发实验室客户。CRO 业务毛利率基本保持相对稳定水平，具体受服务类型、项目内容影响有所波动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-14/doc-inirveaq9305051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4231","NETL","BK4080","BK1574","MEDX","ADC","IBBQ","06978","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667666143","title":"智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667666143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 20:45","pubTimestamp":1789389921,"startTime":"0","endTime":"0","summary":"科技股的走弱，和 Anthropic、OpenAI 与 SpaceX 罕见联手集体呼吁放缓AI 开发步伐有关。业绩方面，多光谱 AI 大模型服务收入冲到 3.20 亿元，同比暴涨 382.5%，收入占比直接从 29.8% 飙升至 78%。机构认为，2026 年 WCLC 大会的主角仍是 IO2.0 与 ADC，肺癌领域尤其是 1L 非小细胞肺癌的标准治疗范式正处于迭代前夜，国产双抗与 ADC 的进度全球领先。授权品种的里程碑付款与商业化分成，正在成为创新药企业价值兑现的第二曲线。这是公司首款双抗 ADC 获批临床，也是公司第三款 ADC 创新药进入临床。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHAT","06978","LU0348735423.USD","01193","BK1566","IE00B543WZ88.USD","06160","LU0307460666.USD","02688","LU0593848301.USD","IE00BPRC5H50.USD","IE00BZ08YS42.EUR","VXUS","IE00BMCWC346.EUR","BK1521","AGIX","VTHR","LU0431992006.USD","LNGR","LU0651946864.USD","LU1051768304.USD","LU1515016050.SGD","MEDX","LU0877626530.USD","IE00BZ08YR35.GBP","159992","QTOC","BK1500","IE00BGHQDM52.EUR","ARTY","AIPO","KCAI","LU1969619763.USD","09969","BK1161","LU0640798160.USD","LU0821914370.USD","LU1808992512.USD","00135","IE0008369823.USD","IE00BZ08YT58.USD","BK4588","LU0287142896.SGD","LU1224709979.USD","KURE","IBBQ","06690","BK1574","IE00B29SXG58.USD","IE0034224299.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":2,"totalSize":341,"code":"91000000","status":"200"}]}}